NILO Therapeutics


Nilo Therapeutics is a biotechnology company launched to develop medicines that target neural circuits to treat immune diseases. The company announced a $101 million Series A financing and the appointment of Kim Seth as CEO to advance a pipeline of neuro-immune therapeutics.

Industries

biotechnology
health-care
therapeutics
wellness

Nr. of Employees

small (1-50)

NILO Therapeutics

New York, New York, United States, North America


Products

Pipeline of medicines targeting neural circuits in immune disease

A pipeline of therapeutic candidates designed to treat immune-mediated diseases by modulating specific neural circuits that influence immune responses.

Expertise Areas

  • Neuroimmunology
  • Therapeutic discovery and development
  • Translational R&D
  • Biotech fundraising and company formation

Key Technologies

  • Neuroimmune modulation
  • Targeted therapeutic development
  • Preclinical models for immune disease
  • Drug discovery platforms

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.